<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407106</url>
  </required_header>
  <id_info>
    <org_study_id>027-15-KMC</org_study_id>
    <nct_id>NCT02407106</nct_id>
  </id_info>
  <brief_title>Efficacy of BLIS K12 as Preventive Measure for Rheumatic Children</brief_title>
  <official_title>Efficacy of Streptococcus Salivarius BLIS (Bacteriocin-like Inhibitory Substance) K12 as Preventive Measure for Rheumatic Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaplan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaplan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether daily treatment with Streptococcus
      Salivarius BLIS K-12 prevents streptococcal throat infection in children that have had an
      episode of rheumatic fever.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children diagnosed with Rheumatic fever are currently given preventive streptococcal
      treatment with either monthly IM (intramuscular injection) Penicillin or daily oral
      Penicillin.

      This preventive treatment is recommended for years until the child is 20 y old or even later.
      The compliance rate for this treatment declines significantly with time (the injections are
      painful) and even with good adherence the prevention is not complete.

      In the last few years a new product licensed as &quot;BLIS K-12&quot; has been developed and approved
      by FDA as GRAS (generally recognized as safe) status from 2011.

      This probiotic treatment prevents the pathogenic Strep A from adhering to the throat of the
      child thus preventing the infection. This kind of prevention is better for the long run for
      the patient and for the surrounding, It is better tolerated, is effective even if a dose is
      skipped or missed is not painful and is tasty to the children.

      So the investigators assumption is that giving this product to children instead of Penicillin
      either orally or intramuscularlly will be better tolerated thus give a better protection
      profile with much less side effects.

      The investigators will be giving BLIS K-12 to those children on the trial on a daily basis
      for 6 autumn-winter months instead of Penicillin and will monitor the children by monthly
      throat swabs. The investigators will also obtain Anti Streptolysin blood test at the end of
      the period from all participants to evaluate possible Strep encounters.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of Strep throat infections while in study</measure>
    <time_frame>six month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rheumatic Fever</condition>
  <arm_group>
    <arm_group_label>BLIS K12 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily tablet of Streptococcus Salivarius BLIS K 12 to be slowly dissolved orally every evening for six month</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Streptococcus Salivarius BLIS K12</intervention_name>
    <description>Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.</description>
    <arm_group_label>BLIS K12 treatment</arm_group_label>
    <other_name>Bio-BLIS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatic heart disease with recommended strep prophylaxis

        Exclusion Criteria:

          -  less than one year from first diagnosis

          -  refusal to take the tablets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yael Garty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attending physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yael Garty, MD</last_name>
    <phone>+972-52-3413184</phone>
    <email>yaelga@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ofra Goldzweig, MD</last_name>
    <phone>+972-50-5525538</phone>
    <email>ofragol@clalit.org.il</email>
  </overall_contact_backup>
  <reference>
    <citation>May G, Wilson MG, Lubschez R. Recurrence rates in rheumatic fever. JAMA. 1944, Vol. 126, 8, pp. 477-480.</citation>
  </reference>
  <reference>
    <citation>Spagnuolo M, Pasternack B, Taranta A. Risk of rheumatic-fever recurrences after streptococcal infections. Prospective study of clinical and social factors. N Engl J Med. 1971 Sep 16;285(12):641-7.</citation>
    <PMID>4254612</PMID>
  </reference>
  <reference>
    <citation>FEINSTEIN AR, WOOD HF, EPSTEIN JA, TARANTA A, SIMPSON R, TURSKY E. A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children. II. Results of the first three years of the study, including methods for evaluating the maintenance of oral prophylaxis. N Engl J Med. 1959 Apr 2;260(14):697-702.</citation>
    <PMID>13644570</PMID>
  </reference>
  <reference>
    <citation>Lue HC, Wu MH, Hsieh KH, Lin GJ, Hsieh RP, Chiou JF. Rheumatic fever recurrences: controlled study of 3-week versus 4-week benzathine penicillin prevention programs. J Pediatr. 1986 Feb;108(2):299-304.</citation>
    <PMID>3511209</PMID>
  </reference>
  <reference>
    <citation>John D.F. Hale, John R. Tagg, and Philip A. Wescombe. BLIS-producing probiotics targeting the oral cavity. Microbiology Australia. 2012, Vol. 33, 3, pp. 103-105.</citation>
  </reference>
  <reference>
    <citation>Barretto C, Alvarez-Martin P, Foata F, Renault P, Berger B. Genome sequence of the lantibiotic bacteriocin producer Streptococcus salivarius strain K12. J Bacteriol. 2012 Nov;194(21):5959-60. doi: 10.1128/JB.01268-12.</citation>
    <PMID>23045482</PMID>
  </reference>
  <reference>
    <citation>J. Tagg, P. Wescombe , J. Burton. Oral streptococcal BLIS: Heterogeneity of the effector molecules and potential role in the prevention of streptococcal infections. International Congress Series. 2006, Vol. 128, pp. 347-350.</citation>
  </reference>
  <reference>
    <citation>Wescombe PA, Upton M, Dierksen KP, Ragland NL, Sivabalan S, Wirawan RE, Inglis MA, Moore CJ, Walker GV, Chilcott CN, Jenkinson HF, Tagg JR. Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol. 2006 Feb;72(2):1459-66.</citation>
    <PMID>16461700</PMID>
  </reference>
  <reference>
    <citation>Di Pierro F, Colombo M, Zanvit A, Risso P, Rottoli AS. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug Healthc Patient Saf. 2014 Feb 13;6:15-20. doi: 10.2147/DHPS.S59665. eCollection 2014.</citation>
    <PMID>24600248</PMID>
  </reference>
  <reference>
    <citation>Burton JP, Chilcott CN, Wescombe PA, Tagg JR. Extended Safety Data for the Oral Cavity Probiotic Streptococcus salivarius K12. Probiotics Antimicrob Proteins. 2010 Oct;2(3):135-44. doi: 10.1007/s12602-010-9045-4.</citation>
    <PMID>26781236</PMID>
  </reference>
  <reference>
    <citation>Burton JP, Cowley S, Simon RR, McKinney J, Wescombe PA, Tagg JR. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol. 2011 Sep;49(9):2356-64. doi: 10.1016/j.fct.2011.06.038. Epub 2011 Jun 21.</citation>
    <PMID>21722694</PMID>
  </reference>
  <reference>
    <citation>Di Pierro F, Donato G, Fomia F, Adami T, Careddu D, Cassandro C, Albera R. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991-7. doi: 10.2147/IJGM.S38859. Epub 2012 Nov 30.</citation>
    <PMID>23233809</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaplan Medical Center</investigator_affiliation>
    <investigator_full_name>Dr Yael Garty MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>BLIS K12</keyword>
  <keyword>streptococcus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Rheumatic Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

